In a comment to our paper reporting an increase in the activity of the interleukin (IL)-23/IL-17 (Th17) cytokine axis in obese women, 1 Chen 2 suggests that IL-17 might have a role in the development of obesity-related cancer. This indeed seems to be a plausible assumption in light of the recent experimental evidence supporting the involvement of IL-17 signalling in carcinogenesis. 2 In relation to this problem, one should also bear in mind the ability of IL-17 to stimulate production of nitric oxide (NO), a pleiotropic free radical with a complex role in tumour progression. 3 In contrast to the anticancer effects of high NO amounts generated by activated macrophages or NO-releasing compounds, low levels of NO produced by tumour cells and/or surrounding stroma apparently promote tumour growth through vasodilatation and angiogenesis. 3 Others and we have recently demonstrated that IL-17 can trigger the expression of inducible NO synthase and subsequent NO production in various cell types through Janus kinase/signal transducers and activators of transcription/interferon regulatory factor-1, mitogen-activated protein kinase/activator protein-1 and tumour necrosis factor receptor-associated factor/nuclear factor-kB signalling pathways. 4 Interestingly, although readily activating inducible NO synthase in endothelial cells, fibroblasts, astrocytes and some tumour cell lines, IL-17 was completely unable to stimulate NO production in macrophages. 4 In contrast, the activity of the IL-12/interferon-g (Th1) cytokine axis, which apparently was not increased in obese women, 1 has been regarded as crucial for stimulation of NO-dependent macrophage anticancer responses. 4, 5 Therefore, it is conceivable to assume that a shift of balance between Th1 and Th17 responses towards the latter, as seen in obesity, 1 could contribute to cancer progression through selective low-level inducible NO synthase activation in tumour and/or surrounding stromal cells. Such an assumption is consistent with the ability of IL-17 to promote tumour growth via stimulation of endothelial cell migration and up-regulation of pro-angiogenic factors in fibroblasts and cancer cells. 6 It should be noted, however, that IL-17 has also been found to activate tumour-specific cytotoxic CD8 þ T cells, thus restricting tumour growth in vivo. 7 Although this suggests a complex, context-dependent role of IL-17 in cancer, its possible involvement in development and progression of obesity-related cancer, as suggested by Chen, 2 seems worthy of further investigation.
